Inactive Instrument

Cardax Inc Stock OTC Bulletin Board

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

21-09-15	Cardax, Inc. announced a financing transaction	CI
21-08-31	Cardax, Inc. Announces Restructuring of Board of Directors	CI

Cardax, Inc. is a geroscience company focused on pharmaceutical and nutraceutical applications of astaxanthin. The Company markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. The Company is also advancing CDX-101, its pharmaceutical candidate, for the diseases of aging. CDX-101 is an astaxanthin Rx candidate for cardiovascular inflammation and dyslipidemia. CDX-301 is its zeaxanthin pharmaceutical candidate for macular degeneration. It may seek to monetize its CDX-301 pharmaceutical assets through licensing or sale.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	413K 356K 335K 306K 571K 38.99M 576K 3.97M 1.54M 19.94M 1.55M 1.52M 65.49M	P/E 2019	-1.36x	P/E 2020	-0.27x
Enterprise Value	5.17M 4.46M 4.21M 3.83M 7.16M 489M 7.22M 49.79M 19.32M 250M 19.43M 19.01M 821M	EV / Sales 2019	13,421,701x	EV / Sales 2020	11,249,008x
Free-Float	100%	Yield 2019 *	-	Yield 2020	-

21-09-15	Cardax, Inc. announced a financing transaction	CI
21-08-31	Cardax, Inc. Announces Restructuring of Board of Directors	CI
21-05-14	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-01-10	Cardax, Inc. announced that it expects to receive $10 million in funding from US Capital Global Investment Management, LLC	CI
20-11-17	Cardax, Inc. announced that it expects to receive $10 million in funding	CI
20-11-13	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-14	Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-05-15	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-03-30	Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-03-15	Cardax, Inc. announced that it expects to receive $0.46 million in funding	CI
20-02-03	Cardax, Inc. has Changed its Ticker to CDXI from CDXID	CI
20-01-20	Cardax, Inc. announced that it expects to receive $0.25 million in funding from Harbor Gates Capital, LLC	CI
19-11-14	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI

21-08-11	CARDAX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21-08-11	Cardax : Voluntarily Suspends SEC Reporting Obligations	PR
21-07-01	CARDAX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	AQ
21-05-14	CARDAX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
21-05-14	Cardax : Reports Q1 2021 Results	PR

Manager	Title	Age	Since
David G. Watumull CEO	Chief Executive Officer	76	2014-02-06
David Watumull DFI	Director of Finance/CFO	44	2021-07-31
Gilbert Shin SAM	Sales & Marketing	-	2017-10-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.97%	-0.75%	+3.51%	+17.79%	49.74B
REVOLUTION MEDICINES, INC.	-1.42%	-3.71%	+424.79%	+515.76%	44.98B
IQVIA HOLDINGS INC.	+1.49%	+0.21%	+42.63%	+18.64%	42.52B
BEONE MEDICINES AG	+0.77%	-3.46%	+9.26%	+77.11%	40.78B
CELLTRION, INC.	-0.90%	-1.74%	+15.20%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+1.26%	+5.49%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+0.19%	-5.82%	+23.18%	+119.93%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-0.05%	+18.53%	+28.09%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.96%	-3.56%	+76.49%	+39.31%	13.48B
Average	+0.57%	-2.42%	+76.70%	+108.13%	30.24B
Weighted average by Cap.	+0.43%	-2.25%	+92.71%	+127.42%

Cardax Inc Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation : Cardax Inc

Latest news : Cardax Inc

Press Releases : Cardax Inc

Managers and Directors : Cardax Inc

Other Biotechnology & Medical Research

Financials

Company Profile

	2019	2020
Net sales	0.71 0.61 0.58 0.53 0.98 67.16 0.99 6.84 2.65 34.34 2.67 2.61 112.79	0.54 0.46 0.44 0.4 0.75 50.91 0.75 5.19 2.01 26.03 2.02 1.98 85.51
Net income	-5.09M -4.39M -4.14M -3.77M -7.05M -481M -7.1M -49M -19.02M -246M -19.12M -18.71M -808M	-5.06M -4.36M -4.11M -3.74M -7M -478M -7.05M -48.64M -18.88M -244M -18.98M -18.57M -802M
Net Debt	2.58M 2.22M 2.09M 1.91M 3.57M 243M 3.59M 24.79M 9.62M 124M 9.67M 9.46M 409M	4.76M 4.11M 3.87M 3.53M 6.59M 450M 6.64M 45.82M 17.78M 230M 17.88M 17.49M 755M